Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride.
about
Systemic delivery of β-blockers via transdermal route for hypertensionElastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activityTopical propranolol therapy for infantile hemangiomas.Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application.Lipid Vesicles for the Skin Delivery of Diclofenac: Cerosomes vs. Other Lipid Suspensions.Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug.Formulation and characterization of Phospholipon 90 G and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate.Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation.Vesicles as tools for the modulation of skin permeability.Solid lipid nanoparticles of guggul lipid as drug carrier for transdermal drug deliveryProgress towards a needle-free hepatitis B vaccine.Transdermal immunization: biological framework and translational perspectives.Skin permeation behavior of elastic liposomes: role of formulation ingredients.Advances in the formulations of non-injection administration of docetaxel.Elastic liposomes as novel carriers: recent advances in drug delivery.Development of a nanogel formulation for transdermal delivery of tenoxicam: a pharmacokinetic-pharmacodynamic modeling approach for quantitative prediction of skin absorption.Could nanovesicles containing a penetration enhancer clinically improve the therapeutic outcome in skin fungal diseases?Liposomal butamben gel formulations: toxicity assays and topical anesthesia in an animal model.Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery.Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate.Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation.Development of aceclofenac nanovesicular system using biomaterial for transdermal delivery: physical characterization, ex vivo, in vivo, and anti-inflammatory studies.Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.Combined mixture-process variable approach: a suitable statistical tool for nanovesicular systems optimization.Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation.Formulation and evaluation of guggul lipid nanovesicles for transdermal delivery of aceclofenac
P2860
Q26772083-F914CD34-E590-4DBA-907D-2C968619EDC4Q33405288-83575A9A-EB5C-4ADA-854C-67E8DBA2DA2EQ34091598-3B4C98B3-EE83-4697-9A50-818E135DBEBDQ34212094-EAC35328-FB09-412A-BC91-4CB15010C458Q35155299-FD47D17A-9921-469E-8098-51750DB75871Q36268597-A8365DD1-0FC7-4CB1-8C53-468233AD1A12Q36371659-9BA32484-B7C7-4F63-B64C-AB3509A490C5Q36482110-D1F50073-23D6-4094-80A6-4FE6442F2548Q36985889-C3036FD0-58B2-459F-822F-A2128C153149Q37154894-15EF4715-D354-4C70-93F6-BE9BDCC6054CQ37810816-3BDF05D3-1F9E-4BFE-B0CE-ABB162C43173Q38068975-36314B7E-9DAF-4641-90F7-5559D4C30983Q38095492-A77B90C4-14BA-454C-B74D-6A25F457AED2Q38149881-CC5209A5-4740-4EAF-9C6B-EFB702FAE5B3Q38648991-56172211-36A2-493E-BE28-6EDEB8800737Q39136890-DAE4F100-562A-48F2-ABDE-AF562B4EC89DQ41127740-71572E5A-4F00-4CA2-8AE2-1DD1A9EFAC36Q42811205-91CA0376-ED2E-4B69-9022-11973BBEA9E8Q43253529-D40E5701-138E-4543-86D3-1F6647B6DADBQ44047766-CEC73460-E2AA-4D79-A86F-C83C9F6DDFC9Q46278013-D21D60B5-1315-4908-B432-DF16EEBC486DQ46424615-F28E2A0C-3D86-44EE-9315-AB024C0E3E8AQ46506603-AB0BB799-3ABB-4E94-9CD7-2EF37B90D97EQ46939179-38693F97-0D3A-46D5-B60D-77E1DB8CBD22Q53152602-8D865EF9-E86C-48E3-B5B2-47A090D50530Q59100464-0289A769-B9E1-4718-8AE0-B6E06A14166F
P2860
Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Elastic liposomes mediated tra ...... nt: propranolol hydrochloride.
@ast
Elastic liposomes mediated tra ...... nt: propranolol hydrochloride.
@en
type
label
Elastic liposomes mediated tra ...... nt: propranolol hydrochloride.
@ast
Elastic liposomes mediated tra ...... nt: propranolol hydrochloride.
@en
prefLabel
Elastic liposomes mediated tra ...... nt: propranolol hydrochloride.
@ast
Elastic liposomes mediated tra ...... nt: propranolol hydrochloride.
@en
P2093
P356
P1476
Elastic liposomes mediated tra ...... ent: propranolol hydrochloride
@en
P2093
Minakshi Garg
Subheet Jain
Vaibhav Dubey
P304
P356
10.1002/JPS.20737
P407
P577
2007-01-01T00:00:00Z